Carbapenem-Based Antibiotics Market is expected to reach US$ 5,346.62 Million by 2028

Others Segment By Type to Hold Largest Share of Carbapenem-Based Antibiotics Market During 2021–2028

According to our new research study on "Carbapenem-Based Antibiotics Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by Type, Indication, and Distribution Channel," the market size is expected to reach US$ 5,346.62 million by 2028 from US$ 3,964.57 million in 2021; it is estimated to grow at a CAGR of 4.4% from 2021 to 2028. The report highlights trends prevailing in the market and factors governing its growth. The growing prevalence of gram-negative bacterial infections and the increasing production of generic drugs fuel the growth of the market. However, tedious and expensive process of antibiotic development hinders the market growth.

Based on type, the carbapenem-based antibiotics market is segmented into meropenem, doripenem, imipenem, tebipenem, and others. The others segment held the largest share of the market in 2021 and is expected to register the highest CAGR during the forecast period. The others segment consists of drugs such as Ertapenem, Vabomere, and Sulopenem (pending FDA approval) that falls under the carbapenem family. The drugs are used to treat various bacterial infections caused by gram negative bacteria. Many infections, such as includes cUTIs, bronchopulmonary infection, complicated intra-abdominal infections, Acute pelvic infections, lower respiratory tract infections, gynecologic infections, and pseudomonas infections, can be treated with carbapenem-based antibiotics treatment. The segment is expected to contribute significantly to the growth of the carbapenem-based antibiotics market due to constant developments in the pharmaceutical industry, increasing incidence of bacterial infections, and growing regulatory approvals for drugs.  

Carbapenem-Based Antibiotics Market

---

Carbapenem-Based Antibiotics Market Size | Report 2021, 2028

Download Free Sample

---

Carbapenem-Based Antibiotics Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type (Meropenem, Doripenem, Imipenem, Tebipenem, and Others), Indication (Bacterial Meningitis, Acute Pelvic Infections, Respiratory Tract Infections, Intra-Abdominal Infections, Urinary Tract Infections, and Others), and Distribution Channel (Retail Pharmacies, Online Pharmacies, and Hospital Pharmacies)

Impact of COVID-19 Pandemic on Carbapenem-Based Antibiotics Market
The COVID-19 pandemic has adversely affected the healthcare industries across the world. The restricted businesses across the world has moderately affected the pharmaceutical industry. The industry has experienced high demand for the antibiotics as a symptomatic treatment for COVID-19 positive patients. Various manufacturers have increased their production of antibiotics during the pandemic. Similarly, there was increase in the demand for antibiotics that can treat HAI, VAP, and AMR. The gram-negative bacterial infection  incidences have been increased as side effects of COVID-19. For instance, in North America, the COVID-19 outbreak has severely affected the pharmaceutical production, as the supply of raw materials was blocked from the supplier regions. Also, the travelling restrictions has stopped vaccination for travellers, which has dropped demand for travel vaccines in the region. In addition, research institutes, pharmaceutical, and biotech companies are engaged in collaborative work to address the COVID-19 outbreak. This has eventually shifted their focus from development of new antibiotics to vaccine development for COVID-19. Healthcare systems are under tremendous pressure due to simultaneous involvement in several processes.  Death count due to COVID-19 is rising exponentially. Moreover, diversion of resources from antibiotics development to COVID-19_treatment is likely to hamper overall productivity of the drug development during the forecast period. For instance, according to a data published on a science blog in February 2020, the COVID-19pandemic will put high pressure on the pipeline for antibiotics and carbapenem-based antibiotics, which is heavily reliant on components from China. Furthermore, pharmaceutical supplies and procurement are also badly affected by the pandemic in North America.

In the current scenario, lifting of the ban from travelling has offered opportunities to the market by resuming trade between countries. It is also expected that the supply chain will enhance the production of antibiotics and carbapenem-based antibiotics and will meet the increasing demand in the future.

Pfizer Inc.; Savior Lifetec; Sumitomo Dainippon Pharma Co., Ltd.; Merck & Co., Inc.; Gland Pharma Limited; Aurobindo Pharma Ltd; Daewoong Pharmaceutical Co.,Ltd; Iterum Therapeutics plc; ACS Dobfar S.p.A, and Spero Therapeutics are among the leading companies operating in the carbapenem-based antibiotics market.

The report segments the global carbapenem-based antibiotics market as follows:

The carbapenem-based antibiotics market is segmented on the basis of type, indication, and distribution channel. Based on type, the carbapenem-based antibiotics market is segmented into meropenem, doripenem, imipenem, tebipenem, and others. Based on indication, the carbapenem-based antibiotics market is segmented into bacterial meningitis, acute pelvic infections, respiratory tract infections, intra-abdominal infections, urinary tract infections, and others. By distribution channel, the carbapenem-based antibiotics market is segmented into retail pharmacies, online pharmacies, and hospital pharmacies.

Contact Us
 
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com